Cordlife Group (P8A) Fundamentals 2026 — Revenue Analysis | SniperIQ
Cordlife Group (P8A) is a SG-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of S
Cordlife Group (P8A) has a market capitalization of approximately S
Cordlife Group's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Cordlife Group runs a net profit margin of -32.0%, a gross margin of 56.7%, and an operating margin of -35.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Cordlife Group reported revenue of S
Cordlife Group does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Cordlife Group carries a debt-to-equity ratio of 0.04x and a current ratio of 2.53x, with a market beta of 0.65. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Cordlife Group (P8A) the key facts are: market cap S
Get Cordlife Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.